About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker RARE · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 4, 2026Tumor-induced Osteomalacia Disease Monitoring Program
NCT04783428 · Tumor-induced Osteomalacia (TIO)
No intervention
RARE
Ultragenyx Pharmaceutical Inc
—Active, not recruiting23Feb 28, 2032Registry ↗
Nov 3, 2026A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Synd…
NCT07157254 · Angelman Syndrome
No intervention, GTX-102
RARE
Ultragenyx Pharmaceutical Inc
Phase 2Terminated
was active, not recruiting
55Oct 30, 2026Registry ↗
Nov 3, 2026Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
NCT06617429 · Angelman Syndrome
GTX-102, Sham-LP
RARE
Ultragenyx Pharmaceutical Inc
Phase 3Terminated
was active, not recruiting
129Jul 10, 2026Registry ↗
Nov 3, 2026Long-term Extension of GTX-102 in Angelman Syndrome
NCT06415344 · Angelman Syndrome
GTX-102
RARE
Ultragenyx Pharmaceutical Inc
Phase 3Terminated
was active, not recruiting
66Oct 30, 2026Registry ↗
Oct 20, 2026Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
NCT05768854 · Osteogenesis Imperfecta
Bisphosphonate, Setrusumab
RARE
Ultragenyx Pharmaceutical Inc
Phase 3Active, not recruiting69Oct 23, 2025Registry ↗
Oct 20, 2026Setrusumab vs Placebo for Osteogenesis Imperfecta
NCT05125809 · Osteogenesis Imperfecta
Setrusumab, Placebo
RARE
Ultragenyx Pharmaceutical Inc
Phase 2/3Active, not recruiting183Oct 20, 2025Registry ↗
Oct 14, 2026Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
NCT06636383 · Glycogen Storage Disease Type Ia
No Intervention
RARE
Ultragenyx Pharmaceutical Inc
—Recruiting140Dec 2036Registry ↗
Oct 14, 2026A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Pat…
NCT05139316 · Glycogen Storage Disease Type IA
DTX401, Placebo
RARE
Ultragenyx Pharmaceutical Inc
Phase 3Completed52Feb 20, 2024Registry ↗
Oct 13, 2026First-in-human Study of UX016 in GNEM
NCT07511556 · GNE Myopathy
UX016, Placebo
RARE
Ultragenyx Pharmaceutical Inc
Phase 1/2Recruiting24Dec 2028Registry ↗
Oct 2, 2026MPS IIIA Disease Monitoring Program
NCT07855562 · MPS IIIA, Sanfilippo Syndrome
No Intervention
RARE
Ultragenyx Pharmaceutical Inc
—Not yet recruiting55Oct 2038Registry ↗
Sep 28, 2026Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta
NCT06636071 · Osteogenesis Imperfecta
setrusumab
RARE
Ultragenyx Pharmaceutical Inc
Phase 3Active, not recruiting6Jan 2027Registry ↗
Sep 25, 2026A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
NCT04884815 · Wilson Disease
UX701, Standard of Care (SOC)
RARE
Ultragenyx Pharmaceutical Inc
Phase 1/2Active, not recruiting82Mar 2029Registry ↗
Sep 22, 2026Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
NCT02716246 · MPS IIIA, Sanfilippo Syndrome
UX111, Prophylactic Immunomodulatory (IM) Therapy
RARE
Ultragenyx Pharmaceutical Inc
Phase 2/3Recruiting36Mar 2029Registry ↗
Sep 17, 2026A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric P…
NCT05933200 · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Triheptanoin, MCT Oil
RARE
Ultragenyx Pharmaceutical Inc
Phase 3Active, not recruiting69Aug 2027Registry ↗
Sep 9, 2026Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency
NCT05345171 · OTC Deficiency
DTX301, Placebo
RARE
Ultragenyx Pharmaceutical Inc
Phase 3Active, not recruiting37Sep 2027Registry ↗
Aug 28, 2026X-linked Hypophosphatemia Disease Monitoring Program
NCT03651505 · X-linked Hypophosphatemia, Hypophosphatemic Rickets
No intervention
RARE
Ultragenyx Pharmaceutical Inc
—Active, not recruiting782Dec 2032Registry ↗
Aug 27, 2026Mucopolysaccharidosis VII Disease Monitoring Program
NCT03604835 · Mucopolysaccharidosis VII, MPS VII
No Intervention
RARE
Ultragenyx Pharmaceutical Inc
—Recruiting50Apr 2032Registry ↗
Jul 31, 2026Expanded Access to Triheptanoin
NCT03773770 · Long Chain Fatty Acid Oxidation Disorders
Triheptanoin
RARE
Ultragenyx Pharmaceutical Inc
—Available——Registry ↗
Jul 30, 2026Expanded Access to Mepsevii
NCT03775174 · MPS VII, Mucopolysaccharidosis VII
Mepsevii
RARE
Ultragenyx Pharmaceutical Inc
—Available——Registry ↗
Jul 17, 2026Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA
NCT04360265 · Mucopolysaccharidosis IIIA, MPS IIIA
No Investigational Product, Adjuvant Immunomodulatory (IM)…
RARE
Ultragenyx Pharmaceutical Inc
Phase 3Enrolling by invitation41Aug 2027Registry ↗
Jun 3, 2026Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program
NCT04632953 · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
No Intervention
RARE
Ultragenyx Pharmaceutical Inc
—Active, not recruiting150Dec 2035Registry ↗
Jun 1, 2026Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency
NCT03636438 · Ornithine Transcarbamylase (OTC) Deficiency
No Intervention
RARE
Ultragenyx Pharmaceutical Inc
—Active, not recruiting11Dec 2029Registry ↗
Mar 18, 2026Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia
NCT03970278 · Glycogen Storage Disease Type IA, Von Gierke's Disease (GSD…
No intervention
RARE
Ultragenyx Pharmaceutical Inc
—Completed12Feb 25, 2025Registry ↗
Jan 9, 2026A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome
NCT04259281 · Angelman Syndrome
GTX-102
RARE
Ultragenyx Pharmaceutical Inc
Phase 1/2Completed74Jan 8, 2025Registry ↗
Jul 23, 2025Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
NCT05312697 · Osteogenesis Imperfecta
Setrusumab
RARE
Ultragenyx Pharmaceutical Inc
Phase 2Terminated2Jul 7, 2022Registry ↗
May 29, 2024Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa
NCT04708015 · Glycogen Storage Disease Type IA
No Intervention
RARE
Ultragenyx Pharmaceutical Inc
—Completed15Mar 4, 2022Registry ↗
Apr 16, 2024Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type…
NCT04990388 · Glycogen Storage Disease Type III
UX053, Placebo
RARE
Ultragenyx Pharmaceutical Inc
Phase 1/2Terminated9Mar 20, 2023Registry ↗
Sep 28, 2023Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants…
NCT05196165 · Glycogen Storage Disease Type III
No Intervention
RARE
Ultragenyx Pharmaceutical Inc
—Terminated14Mar 2, 2023Registry ↗
Aug 1, 2023Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolle…
NCT02214160 · Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency…
UX007
RARE
Ultragenyx Pharmaceutical Inc
Phase 2Completed94Dec 3, 2020Registry ↗
Jul 25, 2023Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease
NCT04088734 · MPS IIIA, Sanfilippo Syndrome
ABO-102
RARE
Ultragenyx Pharmaceutical Inc
Phase 1/2Terminated5Mar 10, 2022Registry ↗
Jul 5, 2023A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
NCT03118570 · Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Ty…
setrusumab, Calcium
RARE
Ultragenyx Pharmaceutical Inc
Phase 2Completed112Oct 1, 2019Registry ↗
Jul 3, 2023An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Impe…
NCT03216486 · Osteogenesis Imperfecta
BPS804
RARE
Ultragenyx Pharmaceutical Inc
Phase 2Withdrawn0Nov 1, 2018Registry ↗
Jun 12, 2023Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
NCT04909346 · Ornithine Transcarbamylase Deficiency, Wilson Disease
RARE
Ultragenyx Pharmaceutical Inc
—Terminated51Nov 17, 2022Registry ↗
Mar 24, 2023Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in…
NCT02736188 · Hereditary Inclusion Body Myopathy, Distal Myopathy With Ri…
Aceneuramic Acid Extended-Release Tablets
RARE
Ultragenyx Pharmaceutical Inc
Phase 3Terminated143Jan 10, 2018Registry ↗
Jan 26, 2023Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbam…
NCT02991144 · Ornithine Transcarbamylase (OTC) Deficiency
scAAV8OTC, Reactive Corticosteroid Taper Regimen
RARE
Ultragenyx Pharmaceutical Inc
Phase 1/2Completed16Dec 16, 2021Registry ↗
Nov 18, 2022Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program
NCT04812106 · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
No Intervention
RARE
Ultragenyx Pharmaceutical Inc
—Terminated8Oct 27, 2022Registry ↗
Nov 18, 2022Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia…
NCT03517085 · GSD1
DTX401, steroid regimen
RARE
Ultragenyx Pharmaceutical Inc
Phase 1/2Completed12Nov 2, 2021Registry ↗
Nov 14, 2022Observational Study of Males With Creatine Transporter Deficiency
NCT02931682 · Creatine Deficiency, X-linked
RARE
Ultragenyx Pharmaceutical Inc
—Terminated50Oct 24, 2022Registry ↗
Sep 16, 2022Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Ad…
NCT01406977 · Hypophosphatasia
BPS804
RARE
Ultragenyx Pharmaceutical Inc
Phase 2Completed8Sep 2012Registry ↗
Sep 15, 2022Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mi…
NCT01406548 · Osteopenia, Osteoporosis
BPS804 20mg/Kg, Placebo to 20mg/Kg BPS804
RARE
Ultragenyx Pharmaceutical Inc
Phase 2Completed44Oct 2013Registry ↗
Sep 14, 2022Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease
NCT01806610 · Chronic-kidney Disease Stage 5D on Stable Hemodialysis
BPS804, Placebo
RARE
Ultragenyx Pharmaceutical Inc
Phase 2Withdrawn0Apr 2014Registry ↗
Sep 13, 2022Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disea…
NCT04574830 · Glycogen Storage Disease Type III
No Intervention
RARE
Ultragenyx Pharmaceutical Inc
—Completed18Jun 30, 2022Registry ↗
Apr 29, 2022Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease
NCT04531189 · Wilson Disease
RARE
Ultragenyx Pharmaceutical Inc
—Completed16Mar 25, 2022Registry ↗
Feb 18, 2022Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficie…
NCT04717453 · Ornithine Transcarbamylase Deficiency
No Intervention
RARE
Ultragenyx Pharmaceutical Inc
—Terminated1Dec 15, 2021Registry ↗
Jan 6, 2022Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe…
NCT02971969 · Hemophilia B
RARE
Ultragenyx Pharmaceutical Inc
—Completed6Nov 6, 2021Registry ↗
May 11, 2021Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta
NCT01417091 · Osteogenesis Imperfecta
BPS804
RARE
Ultragenyx Pharmaceutical Inc
Phase 2Completed10Dec 2012Registry ↗
Feb 11, 2021A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-…
NCT01886378 · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), Carnit…
UX007
RARE
Ultragenyx Pharmaceutical Inc
Phase 2Completed29Aug 25, 2016Registry ↗
Aug 28, 2020Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorde…
NCT03768817 · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
No Intervention
RARE
Ultragenyx Pharmaceutical Inc
—Completed20Jun 8, 2020Registry ↗
Jul 30, 2020A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subject…
NCT02432144 · Sly Syndrome, MPS VII
UX003
RARE
Ultragenyx Pharmaceutical Inc
Phase 3Completed12Jan 14, 2019Registry ↗
Jul 30, 2020A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in…
NCT02230566 · MPS 7, Sly Syndrome
UX003, Placebo
RARE
Ultragenyx Pharmaceutical Inc
Phase 3Completed12May 2016Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:05 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances